A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : RGT / response-guided therapy

[Related PubMed/MEDLINE]
Total Number of Papers: 28
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   RGT  (>> Co-occurring Abbreviation)
Long Form:   response-guided therapy
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Resistance-Guided Antimicrobial Therapy Using Doxycycline-Moxifloxacin and Doxycycline-2.5 g Azithromycin for the Treatment of Mycoplasma genitalium Infection: Efficacy and Tolerability. CI, MG
2018 A real world cost effectiveness analysis of interferon-based therapy forHCVnaive super-responders. DAA, HCV
2017 Safety and efficacy of faldaprevir in combination with pegylated interferon alpha-2b and ribavirin in Japanese patients with genotype-1 chronic hepatitis C virus infection. HCV, SVR12
2017 Simeprevir with peginterferon alpha-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study. GT1, PegIFNalpha-2a, RBV, SVR12
2016 Is response guided therapy dead? Low cure rates in patients with detectable hepatitis C virus at week 4 of treatment. APRI, HCV, SVR
2015 Boceprevir in genotype 1 chronic hepatitis C: first experiences in Serbia. HCV, P/R, SVR
2015 HCV RNA assay sensitivity impacts the management of patients treated with direct-acting antivirals. ART, CTM, DAAs, PIs
2015 Is response-guided therapy being applied in the clinical setting? The hepatitis C example. HCV
2015 Network meta-analysis of direct-acting antivirals in combination with peginterferon-ribavirin for previously untreated patients with hepatitis C genotype 1 infection. BOC, DAAs, FAL, NMA, PR, RCTs, SDT, SIM, SOF, SVR, TEL
10  2015 Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized Study. CI, HBsAg, HBV, HCV, HCV-1, OR, SVR
11  2015 Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naive patients with chronic HCV genotype 1 infection (ESSENTIAL II). ALV, HCV
12  2015 Response Guided Interferon Therapy for Genotype 3 of Chronic Hepatitis C: Compliance and Outcome. RVR, SVR
13  2015 Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST-1, QUEST-2 and PROMISE studies. AEs, PBO, PR, PROs, SMV, SVR12
14  2015 Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir. DAAs, HCV, PEG-IFN, SVR
15  2014 Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection. FSS, HCV, PR
16  2014 HCV RNA quantification with different assays: implications for protease-inhibitor-based response-guided therapy. ART, LLOQ, LOD
17  2014 Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1-infected patients in Japan: the DRAGON study. HCV
18  2014 Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. PR, SVR12
19  2014 Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials. AE, BOC/PR, PR
20  2014 Response-guided therapy for hepatitis C genotype 2 and 3 in those with HIV coinfection. PEG-IFN, RBV
21  2014 Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study. AE, HCV, HIV, HIV-1, SVR12
22  2013 Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model. DVR, HCV, RVR, SDT
23  2013 Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. PEG-IFN, RBV, SMV, SVR
24  2013 Response-guided telaprevir therapy in prior relapsers? The role of bridging data from treatment-naive and experienced subjects. eRVR, TVR
25  2013 The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients. EACS, GT, HCV, IL28B, RVR, SVR
26  2013 Treatment of chronic HCV genotype 1 infection with telaprevir: a Bayesian mixed treatment comparison of fixed-length and response-guided treatment regimens in treatment-naive and -experienced patients. CrI, eRVR, FLT, MTC, OR, TVR
27  2012 Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. HCV, SVR
28  2010 [Individualized respond guidance treatment of chronic hepatitis C with combination of peginterferon alpha-2a and ribavirin]. CHC